血总氨酸作为血管疾病的风险因素:欧洲协同行动项目
L El-Khairy1, P M Ueland, H Refsum
1LOCUS for Homocysteine and Related Vitamins, University of Bergen, Bergen, Norway. lina.el-khairy@smis.uib.no
Circulation
|May 31, 2001
概括
血总氨酸 (tCys) 显示出与血管疾病风险的U形联系,低水平和高水平都会增加风险. 这与已知心血管风险因素的总同型半氨酸 (tHcy) 相反.
科学领域:
- 生物化学 生物化学
- 心血管医学 心血管医学
- 流行病学 流行病学
背景情况:
- 血总同型半氨酸 (tHcy) 的升高是已知的心血管疾病 (CVD) 风险因素.
- 血总氨酸 (tCys) 和心血管疾病风险之间的关联尽管与tHcy.的代谢联系,但仍未得到充分研究.
研究的目的:
- 调查血总氨酸 (tCys) 水平与冠状动脉,大脑和外周血管血管血管疾病风险之间的关系.
主要方法:
- 一项涉及9个欧洲国家的750名血管疾病患者和800名对照者的病例控制研究.
- 测量了tCys,tHcy,叶酸,B6和B12以及肌素的血水平.
- 调整为传统的心血管疾病风险因素.
主要成果:
- 在tCys水平和整体血管疾病风险之间观察到显著的U形关系.
- 低TCys水平 (<=225微摩尔/升) 显示调整后风险为2.1 (95% CI 1.2至3.6).
- 与参考水平 (250-275微摩尔/升) 相比,高TCys水平 (>300微摩尔/升) 显示调整后的风险为1.6 (95% CI1.1至2.3).
- 剂量反应关系因血管床而异:对外周和脑血管疾病的U形,对冠心病的弱阳性.
结论:
- 血总氨酸 (tCys) 与心血管疾病风险具有显著的U形关联.
- 在调整了THC,肌素和其他心血管疾病风险因素后,这种关系仍然存在.
- 这些发现突出了tCys作为血管疾病风险的潜在独立标志物.
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
973
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
973
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


